The potential role of community-based registries to complement the limited applicability of clinical trial results to the community setting: Heart failure as an example

American Journal of Managed Care

Volumn 10, Issue 7 II, 2004, Pages 487-492

  Franciosa, Joseph A ^a,b  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARVEDILOL;

COMMUNITY CARE; DATA BASE; EVIDENCE BASED MEDICINE; HEART FAILURE; HUMAN; OUTCOMES RESEARCH; PRACTICE GUIDELINE; PRIORITY JOURNAL; REGISTER; REVIEW; TECHNOLOGY;

ADRENERGIC BETA-ANTAGONISTS; CLINICAL TRIALS; COMMUNITY HEALTH SERVICES; HEART FAILURE, CONGESTIVE; HUMANS; REGISTRIES; UNITED STATES;

EID: 3242753497     PISSN: 10880224     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (40)

1. Tunis SR, Stryer DB, Clancy CM. Practical clinical trials: increasing the value of clinical research for decision making in clinical and health policy. JAMA. 2003;290:1624-1632.
2. Wells KB. Treatment research at the crossroads: the scientific interface of clinical trials and effectiveness research. Am J Psychiatry. 1999;156:5-10.
3. Weinberger M, Oddone EZ, Henderson WG, et al. Multisite randomized controlled trials in health services research: scientific challenges and operational issues. Med Care. 2001;39:627-634.
4. ACC/AHA Task Force on Practice Guidelines. Guidelines for the evaluation and management of heart failure: report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Evaluation and Management of Heart Failure). Circulation. 1995;92:2764-2784.
5. Packer M, Cohn IN, Steering Committee and Membership of the Advisory Council to Improve Outcomes Nationwide in Heart Failure. Consensus recommendations for the management of chronic heart failure. Am J Cardiol. 1999;83:1A-38A.
6. Hunt SA, Baker DW, Chin MH, et al. ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to revise the 1995 Guidelines for the Evaluation and Management of Heart Failure). J Am Coll Cardiol. 2001;38:2101-2113.
7. Foody JM, Farrell MH, Krumholz HM. β-blocker therapy in heart failure: scientific review. JAMA. 2002;287:883-889.
8. Farrell MH, Foody JM, Krumholz HM. β-blockers in heart failure: clinical application. JAMA. 2002;287:890-897.
9. Senni M, Tribouilloy CM, Rodeheffer RJ, et al. Congestive heart failure in the community: study of all incident cases in Olmsted County, Minnesota, in 1991. Circulation. 1998;98:2282-2289.
10. Sharpe N. Heart failure in the community. Progr Cardiovasc Dis. 1998;41 (suppl 1):73-76.
11. Lindenfeld J, Krause-Steinrauf H, Salerno J. Where are all the women with heart failure? J Am Coll Cardiol. 1997;30:1417-1419.
12. Dauterman KW, Go AS, Rowell R, Gebretsadik T, Gettner S, Massie BM. Congestive heart failure with preserved systolic function in a statewide sample of community hospitals. J Card Fail. 2001;7:229-231.
13. Gottdiener JS, McClelland RL, Marshall R, et al. Outcome of congestive heart failure in elderly persons: influence of left ventricular systolic function: the Cardiovascular Health Study. Ann Intern Med. 2002;137:631-639.
14. Zile MR. Heart failure with preserved ejection fraction: is this diastolic heart failure? J Am Coll Cardiol. 2003;41:1519-1522.
15. McCullough PA, Philbin EF, Spertus JA, Kaatz S, Sandberg KR, Weaver WD. Confirmation of a heart failure epidemic: findings from the Resource Utilization Among Congestive Heart Failure (REACH) study. J Am Coll Cardiol. 2002;39:60-69.
16. Khand A, Gemmel I, Clark AL, Cleland JGF. Is the prognosis of heart failure improving? J Am Coll Cardiol. 2000;36:2284-2286.
17. Senni M, Tribouilloy CM, Rodeheffer RJ, et al. Congestive heart failure in the community: trends in incidence and survival in a 10-year period. Arch Intern Med. 1999;159:29-34.
18. Philbin EF, Rocco TA, Lindenmuth NW, Ulrich K, Jenkins PL. Clinical outcomes in heart failure: report from a community hospital-based registry. Am J Med. 1999;107:549-555.
19. Opasich C, Rapezzi C, Lucci D, et al, Italian Network on Congestive Heart Failure (IN-CHF) Investigators. Precipitating factors and decision-making processes of short-term worsening heart failure despite "optimal" treatment (from the IN-CHF Registry). Am J Cardiol. 2001;88:382-387.
20. Franciosa JA, Abraham WT, Fowler M, et al, COHERE Participant Physicians. Rationale, design, and methods for a Coreg (carvedilol) Heart Failure Registry (COHERE). J Card Fail. 2000;6:264-271.
21. Franciosa JA, Abraham WT, Fowler M, et al, COHERE Participant Physicians. Coreg Heart Failure Registry (COHERE): characteristics of participating physicians, their patients, and dose-titration experience [abstract]. Circulation. 2001;104(suppl 11):11801.
22. Massie BM, Greenberg G, Gilbert EM, et al, COHERE Participant Physicians. Carvedilol initiation by community physicians in COHERE: comparison with US carvedilol trials and compassionate use protocols [abstract]. J Am Coll Cardiol. 2002;39(suppl A):461A.
23. Franciosa JA, Massie BM, Greenberg B, et al, COHERE Participant Physicians. Titration, tolerability, and results of β-blocker therapy for heart failure in the community: findings of a community-based registry [abstract]. J Card Fail. 2003;9(suppl):S96.
24. Packer M, Bristow MR, Cohn JN, et al, US Carvedilol Heart Failure Study Group. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med. 1996;334:1349-1355.
25. Bozkurt B, Agoston I, Knowlton AA. Complications of inappropriate use of spironolactone in heart failure: when an old medicine spirals out of new guidelines. J Am Coll Cardiol. 2003;41:211-214.
26. Carson P, Ziesche S, Johnson G, Cohn IN, Vasodilator-Heart Failure Trial Study Group. Racial differences in response to therapy for heart failure: analysis of the vasodilator-heart failure trials. J Card Fail. 1999;5:178-187.
27. Exner DV, Dries DL, Domanski MJ, Cohn JN. Lesser response to angiotensin-converting enzyme inhibitor therapy in black as compared with white patients with left ventricular dysfunction. N Engl J Med. 2001;344:1351-1357.
28. Yancy CW, Fowler MB, Colucci WS, et al, US Carvedilol Heart Failure Study Group. Race and the response to adrenergic blockade with carvedilol in patients with chronic heart failure. N Engl J Med. 2001;344:1358-1365.
29. Herlitz J, Wikstrand J, Denny M, et al, MERIT-HF Study Group. Effects of metoprolol CR/XL on mortality and hospitalizations in patients with heart failure and history of hypertension. J Card Fail. 2002;8:8-14.
30. Ghali JK, Pina IL, Gottlieb SS, Deedwania PC, Wikstrand JC, MERIT-HF Study Group. Metoprolol CR/XL in female patients with heart failure: analysis of the experience in Metoprolol Extended-Release Randomization Intervention Trial in Heart Failure (MERIT-HF). Circulation. 2002;105:1585-1591.
31. Franciosa JA, Taylor AL, Cohn JN, et al, A-HeFT Investigators. African-American Heart Failure Trial (A-HeFT): rationale, design, and methodology. J Card Fail. 2002;8:128-135.
32. Judge KW, Pawitan Y, Caldwell J, Gersh BJ, Kennedy JW, CASS Participants. Congestive heart failure symptoms in patients with preserved left ventricular systolic function: analysis of the CASS registry. J Am Coll Cardiol. 1991;18:377-382.
33. Pole DJ, Thompson PL, Woodings TL, McCall MG, Reader R. Acute myocardial infarction: one year follow-up or 1138 cases from the Perth Community Coronary Register. Aust N Z J Med. 1976;6:437-440.
34. Bangdiwala SI, Weiner DH, Bourassa MG, Friesinger GC II, Ghali JK, Yusuf S, SOLVD investigators. Studies of Left Ventricular Dysfunction (SOLVD) Registry: rationale, design, methods and description of baseline characteristics. Am J Cardiol. 1992;70:347-353.
35. Ansari M, Alexander M, Tutar A, Bello D, Massie BM. Cardiology participation improves outcomes in patients with new-onset heart failure in the outpatient setting. J Am Coll Cardiol. 2003;41:62-68.
36. Chin MH, Friedmann PD, Cassel CK, Lang RM. Differences in generalist and specialist physicians' knowledge and use of angiotensin-converting enzyme inhibitors for congestive heart failure. J Gen Intern Med. 1997;12:523-530.
37. Edep ME. Shah NB, Tateo IM, Massie BM. Differences between primary care physicians and cardiologists in management of congestive heart failure: relation to practice guidelines. J Am Coll Cardiol. 1997;30:518-526.
38. Auerbach AD, Hamel MB, Davis RB, et al, SUPPORT Investigators. Resource use and survival of patients hospitalized with congestive heart failure: differences in care by specialty of the attending physician: Study to Understand Prognoses and Preferences for Outcomes and Risks of Treatments. Ann Intern Med. 2000;132:191-200.
39. Goldberg RJ, Konstam MA. Assessing the population burden from heart failure: need for sentinel population-based surveillance systems. Arch Intern Med. 1999;159:15-17.
40. US Food and Drug Administration. Pharmacovigilance Planning (PVP). Available at: www.fda.gov.cber/gdlns/ichpvp.htm. Accessed November 11, 2003.